(CercleFinance.com) – UBS reiterates its buy advice on the stock with a price target of E145, which represents an upside potential of 41%.
‘We recognize the likely increase in competition for elafibranor following the acquisition of GILD/CBAY, but note moderate expectations for peak sales of elafibranor.’
‘The experimental drug, administered once daily orally, could become the first new second-line treatment for primary biliary cholangitis, a rare cholestatic liver disease, in almost a decade,’ the group said.
The European Medicines Agency has validated the marketing authorization application for elafibranor. The American FDA has accepted the submission of the authorization application file for the experimental drug elafibranor.
Copyright © 2024 CercleFinance.com. All rights reserved.
The information and analyzes distributed by Cercle Finance only constitute a decision-making aid for investors. Cercle Finance cannot be held responsible directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional advisor before making any investment. This indicative information does not in any way constitute an inducement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends using the buttons below.
